PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to AstraZeneca GmbH

04.07.2005 – 10:01

AstraZeneca GmbH

AstraZeneca to Start Phase III Trials With ZACTIMA (TM) (ZD6474) - a Novel Targeted Lung Cancer Treatment

Barcelona, Spain (ots/PRNewswire)

AstraZeneca (LSE: AZN, NYSE:
AZN) announced today that it is to progress to Phase III studies with
its novel oncology compound ZD6474 - now also known by its trade
name, ZACTIMA (TM). Recruitment to Phase III studies evaluating the
anti-tumour activity of ZACTIMA (TM) (ZD6474) in non-small cell lung
cancer (NSCLC) will begin in the next few months.
ZACTIMA (TM) (ZD6474) is a unique once-daily oral therapy that
Selectively targets key signalling pathways in cancer including:
vascular Endothelial growth factor (VEGF) receptor signalling
resulting in inhibition of tumour angiogenesis; and epidermal growth
factor (EGF) receptor signalling which may lead to direct inhibition
of cancer cell proliferation and survival. ZACTIMA (TM) (ZD6474) also
inhibits RET kinase which may be important in certain tumours.
New data from two Phase II studies - Trials 003 and 006 - with
ZACTIMA (TM) (ZD6474) will be presented at the 11th World Conference
on Lung Cancer in Barcelona, Spain, on Wednesday, July 6. Trial 003
compares ZACTIMA (TM) (ZD6474) monotherapy with gefitinib (IRESSA(R))
monotherapy in patients with advanced NSCLC.
Preliminary results of Trial 006, presented at the American
Society of Oncology (ASCO) Annual Meeting in May 2005, assessed the
anti-tumour efficacy of ZACTIMA (TM) (ZD6474) in combination with
docetaxel (Taxotere(R)) in patients with advanced lung cancer. The
results showed that the primary endpoint of improved progression free
survival (PFS) was met. For the secondary endpoint of overall
survival no significant effect of ZACTIMA (TM) (ZD6474) was observed,
possibly due to the small number of patients involved and the fact
that survival data was potentially confounded by subsequent
therapies.
Both progression free survival and survival outcomes will be
investigated in Phase III trials.
ZACTIMA(TM) (ZD6474) is a trademark of the AstraZeneca group of
companies.

Contact:

Julie Watson, Global PR Manager - Oncology, Mobile: +44-7747-612747,
Julie.Watson@astrazeneca.com. Catherine Hartley, Shire Health
International, Tel: +44-207-108-6500, Mobile: +44-7789-008-047,
Catherine.Hartley@shirehealthinternational.com

Original content of: AstraZeneca GmbH, transmitted by news aktuell

More stories: AstraZeneca GmbH
More stories: AstraZeneca GmbH